| This week's sponsor is Premier Research. | |  | >From Lab to Bedside: The Latest in Rare Oncology Drug Research
Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best. |
Featured Story Thursday, February 16, 2017  Shares in Editas Medicine rose 30% after the U.S. patent office sided with the Broad Institute in the legal tussle over CRISPR gene editing. The board ruled that the inventions claimed by Broad and the University of California are distinct, triggering divergent reactions in the stocks of biotechs built on the work of each academic center.
| This week's sponsor is Charles River. | | Webinar: When to Add PDX Models into Your Oncology Program: IO and non-IO?
Could PDX be the most cost-effective tool for targeted therapies in cancer? How can PDX be incorporated into an immuno-oncology program? Can clinical biomarkers be identified using these models?
Just a few of the questions that we'll discuss in our upcoming webinar providing an overview of our extensive experience with PDX models and best ways to use in your preclinical strategy. Join us. |
Top Stories Thursday, February 16, 2017 Juno took a major hit last year when a number of patients died in its experimental CAR-T test, which for months has remained under a cloud and another halt. But analysts at Leerink see reasons to be cheerful about its second next-gen blood cancer candidate. Thursday, February 16, 2017 uniQure plots to initiate a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance. uniQure aims to move its hemophilia B gene therapy, AMT-060, into a pivotal trial while working to advance a Huntington's disease asset and Bristol-Myers-partnered heart failure candidate into the clinic. Monday, February 13, 2017 An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global increase in Dry Eye Disease. Thursday, February 16, 2017 Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast and skin cancer. Wednesday, February 15, 2017 Integra LifeSciences has made a binding offer to acquire Johnson & Johnson’s Codman Neurosurgery business for about $1.05 billion in cash. | This week's sponsor is Destination Medical Center. | |  | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | Alexion said in its financials that it will stop future studies of its rare disease candidate SBC-103 in MPS IIIB, which it got from its Synageva acquisition, and take an $85 million charge. Release Dauntless Pharmaceuticals said it has started a phase 1 test of its octreotide formulation for intranasal delivery as it also closes a $25 million expansion of its Series A round. Release Xcell Biosciences has seen a $12 million Series A funding boost as it looks to expand efforts for its primary cell culture platform across a host of diseases. Release | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! | 
